Global Liver Cancer Diagnostics Market - Industry Trends and Forecast to 2030
- Published Date: 2023-08-18
- Report ID: 145351
- Pages: 250
-
Format:
The global liver cancer diagnostics market is projected to register a substantial CAGR of 6.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Global Liver Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I , Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and the rest of Asia-Pacific, South Africa, Saudi Arabia, Egypt, Israel and the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America) - Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the global liver cancer diagnostics market are:
Rise in prevalence and incidence of liver cancer in the world
Increase in awareness about the liver cancer diagnostics
Market Players:
Some of the major players operating in the global liver cancer diagnostics market are:
F. Hoffmann-La Roche Ltd.
Koninklijke Philips N.V.
Thermo Fisher Scientific Inc.
BD
Siemens Healthcare GmbH
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN
FUJIFILM Corporation
Sysmex Corporation AB
Scitex Pte Ltd. (Subsidiary of Danaher.)
Epigenomics AG
Tebubio
Fujirebio
Diagnostic Biosystems Inc.
Q-LINE BIOTECH PVT LTD.
MOLGEN
BIOCEPT, INC.
Boditech Med Inc.
Elabscience Biotechnology Inc.
Hipro Biotechnology Co., Ltd.
Altogen Biosystems
Tosoh India Pvt. Ltd.
ABK Biomedical Inc.
Diazyme Laboratories, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 56
1.1 OBJECTIVES OF THE STUDY 56
1.2 MARKET DEFINITION 56
1.3 OVERVIEW OF THE GLOBAL LIVER CANCER DIAGNOSTICS MARKET 56
1.4 CURRENCY AND PRICING 58
1.5 LIMITATIONS 58
1.6 MARKETS COVERED 59
2 MARKET SEGMENTATION 62
2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELLING 69
2.7 MARKET APPLICATION COVERAGE GRID 70
2.8 TEST TYPE LIFELINE CURVE 71
2.9 DBMR MARKET POSITION GRID 72
2.10 VENDOR SHARE ANALYSIS 73
2.11 SECONDARY SOURCES 74
2.12 ASSUMPTIONS 74
3 EXECUTIVE SUMMARY 75
4 PREMIUM INSIGHTS 78
4.1 PESTLE ANALYSIS 81
4.2 PORTER ANALYSIS 82
4.3 EPIDEMIOLOGY 83
5 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 84
6 INDUSTRY INSIGHTS 88
7 MARKET OVERVIEW 90
7.1 DRIVERS 92
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 92
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 93
7.1.3 INCREASING CASES OF LIVER CANCER 95
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 96
7.2 RESTRAINTS 98
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 98
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 99
7.3 OPPORTUNITIES 99
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 99
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 99
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 100
7.4 CHALLENGES 101
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 101
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 102
8 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 103
8.1 OVERVIEW 104
8.2 IMAGING TEST 107
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 108
8.2.1.1 MR ANGIOGRAPHY (MRA) 108
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 109
8.2.2 COMPUTED TOMOGRAPHY 109
8.2.3 POSITRON EMISSION TOMOGRAPHY 109
8.2.4 ULTRASOUND 109
8.2.5 OTHERS 109
8.3 GENOMIC TEST 109
8.4 BIOPSY 110
8.4.1 FINE NEEDLE ASPIRATION BIOPSY 111
8.4.2 CORE NEEDLE BIOPSY 111
8.4.3 LAPAROSCOPY 111
8.5 OTHERS 112
9 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 113
9.1 OVERVIEW 114
9.2 STAGE III 117
9.3 STAGE II 118
9.4 STAGE IV 119
9.5 STAGE I 120
9.6 STAGE 0 121
10 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 122
10.1 OVERVIEW 123
10.2 SECONDARY LIVER CANCER 126
10.2.1 HEMANGIOMA 127
10.2.2 HEPATIC ADENOMA 127
10.2.3 FOCAL NODULAR HYPERPLASIA 127
10.3 PRIMARY LIVER CANCER 127
10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 128
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 128
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 129
10.3.4 HEPATOBLASTOMA 129
11 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 130
11.1 OVERVIEW 131
11.2 PLATFORM BASED PRODUCTS 134
11.2.1 NEXT GENERATION SEQUENCING 135
11.2.2 MICROARRAYS 135
11.2.3 PCR 135
11.2.4 OTHERS 135
11.3 INSTRUMENT BASED PRODUCTS 135
11.3.1 IMAGING 136
11.3.2 BIOPSY 136
11.4 KITS AND REAGENTS 137
11.4.1 ELISA TEST KITS 138
11.4.2 CASSETTE TEST KITS 138
11.4.3 OTHERS 138
11.5 OTHER CONSUMABLES 138
12 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 139
12.1 OVERVIEW 140
12.2 SCREENING 143
12.2.1 PLATFORM BASED PRODUCTS 144
12.2.2 INSTRUMENT BASED PRODUCTS 144
12.2.3 KITS AND REAGENTS 144
12.2.4 OTHER CONSUMABLES 144
12.3 DIAGNOSTIC AND PREDICTIVE 144
12.3.1 PLATFORM BASED PRODUCTS 145
12.3.2 INSTRUMENT BASED PRODUCTS 145
12.3.3 KITS AND REAGENTS 145
12.3.4 OTHER CONSUMABLES 146
12.4 PROGNOSTIC 146
12.4.1 PLATFORM BASED PRODUCTS 147
12.4.2 INSTRUMENT BASED PRODUCTS 147
12.4.3 KITS AND REAGENTS 147
12.4.4 OTHER CONSUMABLES 147
12.5 RESEARCH 147
12.5.1 PLATFORM BASED PRODUCTS 149
12.5.2 INSTRUMENT BASED PRODUCTS 149
12.5.3 KITS AND REAGENTS 149
12.5.4 OTHER CONSUMABLES 149
13 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 150
13.1 OVERVIEW 151
13.2 FLUORESCENT IN SITU HYBRIDIZATION 154
13.3 NEXT GENERATION SEQUENCING 155
13.4 FLUORIMMUNOASSAY 156
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 157
13.6 IMMUNOHISTOCHEMICAL 158
13.7 OTHERS 159
14 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 160
14.1 OVERVIEW 161
14.2 MALE 164
14.3 FEMALE 165
15 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY END USER 166
15.1 OVERVIEW 167
15.2 HOSPITALS 170
15.3 DIAGNOSTIC CENTERS 171
15.4 CANCER RESEARCH CENTERS 172
15.5 AMBULATORY SURGICAL CENTERS 173
15.6 ACADEMIC INSTITUTES 174
15.7 OTHERS 175
16 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 176
16.1 OVERVIEW 177
16.2 DIRECT TENDER 180
16.3 RETAIL SALES 181
16.4 OTHERS 182
17 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY REGION 183
17.1 OVERVIEW 184
17.2 NORTH AMERICA 190
17.2.1 U.S. 203
17.2.2 CANADA 211
17.2.3 MEXICO 219
17.3 EUROPE 227
17.3.1 GERMANY 240
17.3.2 FRANCE 248
17.3.3 RUSSIA 256
17.3.4 ITALY 263
17.3.5 U.K. 271
17.3.6 SPAIN 278
17.3.7 TURKEY 285
17.3.8 NETHERLANDS 292
17.3.9 BELGIUM 300
17.3.10 SWITZERLAND 308
17.3.11 REST OF EUROPE 316
17.4 ASIA-PACIFIC 317
17.4.1 CHINA 328
17.4.2 INDIA 334
17.4.3 JAPAN 340
17.4.4 INDONESIA 346
17.4.5 PHILIPPINES 352
17.4.6 THAILAND 358
17.4.7 AUSTRALIA 364
17.4.8 MALAYSIA 370
17.4.9 SOUTH KOREA 376
17.4.10 SINGAPORE 382
17.4.11 VIETNAM 388
17.4.12 REST OF ASIA-PACIFIC 394
17.5 SOUTH AMERICA 395
17.5.1 BRAZIL 408
17.5.2 ARGENTINA 416
17.5.3 REST OF SOUTH AMERICA 424
17.6 MIDDLE EAST AND AFRICA 425
17.6.1 SOUTH AFRICA 436
17.6.2 SAUDI ARABIA 442
17.6.3 U.A.E. 448
17.6.4 EGYPT 454
17.6.5 ISRAEL 460
17.6.6 REST OF MIDDLE EAST AND AFRICA 466
18 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 467
18.1 COMPANY SHARE ANALYSIS: GLOBAL 467
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 468
18.3 COMPANY SHARE ANALYSIS: EUROPE 469
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 470
19 SWOT ANALYSIS 471
20 COMPANY PROFILE 472
20.1 F. HOFFMANN-LA ROCHE LTD. 472
20.1.1 COMPANY SNAPSHOT 472
20.1.2 REVENUE ANALYSIS 472
20.1.3 COMPANY SHARE ANALYSIS 473
20.1.4 PRODUCT PORTFOLIO 473
20.1.5 RECENT DEVELOPMENT 473
20.2 KONINLIJKE PHILIPS N.V. 474
20.2.1 COMPANY SNAPSHOT 474
20.2.2 REVENUE ANALYSIS 474
20.2.3 COMPANY SHARE ANALYSIS 475
20.2.4 PRODUCT PORTFOLIO 475
20.2.5 RECENT DEVELOPMENT 475
20.3 THERMO FISHER SCIENTIFIC INC. 476
20.3.1 COMPANY SNAPSHOT 476
20.3.2 REVENUE ANALYSIS 476
20.3.3 COMPANY SHARE ANALYSIS 477
20.3.4 PRODUCT PORTFOLIO 477
20.3.5 RECENT DEVELOPMENT 477
20.4 BD 478
20.4.1 COMPANY SNAPSHOT 478
20.4.2 REVENUE ANALYSIS 478
20.4.3 COMPANY SHARE ANALYSIS 479
20.4.4 PRODUCT PORTFOLIO 479
20.4.5 RECENT DEVELOPMENTS 480
20.5 SIEMENS HEALTHCARE GMBH 481
20.5.1 COMPANY SNAPSHOT 481
20.5.2 REVENUE ANALYSIS 481
20.5.3 COMPANY SHARE ANALYSIS 482
20.5.4 PRODUCT PORTFOLIO 482
20.5.5 RECENT DEVELOPMENT 482
20.6 AGILENT TECHNOLOGIES, INC. 483
20.6.1 COMPANY SNAPSHOT 483
20.6.2 REVENUE ANALYSIS 483
20.6.3 PRODUCT PORTFOLIO 484
20.6.4 RECENT DEVELOPMENTS 484
20.7 ABK BIOMEDICAL INC. 485
20.7.1 COMPANY SNAPSHOT 485
20.7.2 PRODUCT PORTFOLIO 485
20.7.3 RECENT DEVELOPMENT 485
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 486
20.8.1 COMPANY SNAPSHOT 486
20.8.2 REVENUE ANALYSIS 486
20.8.3 PRODUCT PORTFOLIO 487
20.8.4 RECENT DEVELOPMENT 487
20.9 ALTOGEN BIOSYSTEMS 488
20.9.1 COMPANY SNAPSHOT 488
20.9.2 PRODUCT PORTFOLIO 488
20.9.3 RECENT DEVELOPMENT 488
20.10 BIOCEPT, INC. 489
20.10.1 COMPANY SNAPSHOT 489
20.10.2 REVENUE ANALYSIS 489
20.10.3 PRODUCT PORTFOLIO 490
20.10.4 RECENT DEVELOPMENT 490
20.11 BODITECH MED INC. 491
20.11.1 COMPANY SNAPSHOT 491
20.11.2 PRODUCT PORTFOLIO 491
20.11.3 RECENT DEVELOPMENTS 491
20.12 DIAGNOSTIC BIOSYSTEMS INC. 492
20.12.1 COMPANY SNAPSHOT 492
20.12.2 PRODUCT PORTFOLIO 492
20.12.3 RECENT DEVELOPMENT 492
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
